C-Path’s Critical Path to Therapeutics for the Ataxias Consortium is pleased to announce the appointment of Irina Antonijevic, M.D., Ph.D., as the consortium’s Industry Co-Director.
Irina has worked in drug development for over 18 years, with a focus on translational medicine and early development in neuroscience, but also ophthalmology and immunology. She has gained experience with development of small molecules, biologics as well as nucleic acid therapeutics, in a number of global pharma and biotech organizations in the U.S. and Europe. Before joining Triplet Therapeutics, Inc., she was VP of Translational Medicine and Development at Wave Life Sciences in Cambridge, MA, developing nucleic acid therapeutics for rare genetic diseases.
Irina has an M.D. from the Technical University, Munich and a Ph.D. in neurophysiology from the University of Edinburgh, UK. She trained in psychiatry and neurology at the Max Planck Institute of Psychiatry, and is board certified in Germany. She obtained her venia legendi at the Charité, Berlin University in 2004.
To learn more about CPTA, visit: https://c-path.org/programs/cpta/.
